Dec. 29, 2020
Applications and Impact of CRISPR/Cas9 in Bioprocessing
WuXi Biologics
Offering End-to-End Solutions
Perspectives
-
-
Oct. 15, 2020The Watershed Moment for ADCs has Arrived -
Sep. 16, 2020Reducing Fill Risk in Drug Product Manufacture Utilizing New State-of-the-Art Systems and Platforms -
Sep. 10, 2021The Challenge of Staying Current with Regulatory Changes – How one company is providing a solution -
Aug. 10, 2021Continuous Biomanufacturing Implementation Using an Intensified and Integrated Bioprocess Platform -
Apr. 20, 2020Fierce Pharma Virtual Series – Expert Panel Discussion Featuring Chris Chen -
Sep. 09, 2019Antibody Drug Conjugate (ADC) Development And Manufacturing Challenges And Solutions -
Aug. 28, 2019New Flexible Bispecific Antibody Format Demonstrates Improved Therapeutic Properties and Manufacturability -
Apr. 11, 2019Biologic Products DNA to IND Timeline in 9 Months – Yes it can be done!
Notice:
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?